The Report
Verified funding, headquarters, and leadership news from the world's most innovative businesses
58 reports and counting
Microbiotica Raises £36M Series C for Oral Microbiome Medicines
Microbiotica announced the first close of a £36 million ($48 million) Series C led by British Business Bank to advance MB310 into Phase 2 clinical development in ulcerative colitis.
OMass Therapeutics Raises $310M Series C for Small-Molecule Therapeutics
OMass Therapeutics raised an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings to advance its small molecule pipeline in endocrinology and immunology.
Harmony Biosciences Appoints Peter Anastasiou President and Chief Executive Officer
Harmony Biosciences appointed Chief Operating Officer Peter Anastasiou as CEO effective January 1, 2027, succeeding retiring CEO Jeffrey M. Dayno, to lead the company’s next phase of growth.
Breye Therapeutics Raises €67.5M Series A for Oral Retinal Disease Drugs
Breye Therapeutics raised an over-subscribed €67.5 million Series A co-led by Mission BioCapital and Novo Holdings to advance danegaptide into a Phase 2 trial.
Basecamp Research Raises $140M Series C for AI-Designed Medicines
Basecamp Research raised a $140 million Series C led by S32 to train new EDEN models and advance AI-designed therapeutics toward clinical development.
Legend Biotech Appoints Ingrid Zhang Chief Executive Officer
Legend Biotech appointed former Novartis International Chief Commercial Officer Ingrid Zhang as CEO, succeeding Interim CEO Alan Bash, to guide the cell therapy company’s next phase of growth.
Chiesi Appoints David Khougazian Group Chief Executive Officer
Chiesi appointed former Flagship Pioneering executive David Khougazian as Group CEO, succeeding Interim Group CEO Jean-Marc Bellemin, to lead its next phase of innovation-driven growth.
Protein2o Names Mark Rappaport Chief Executive Officer
Protein2o appointed Mark Rappaport, most recently Global Chief Commercial Officer of Congo Brands, as Chief Executive Officer and a member of its Board of Directors, and announced a new growth investment.
Robertshaw Appoints Dibyava Ghosh Chief Executive Officer
Robertshaw’s Board of Directors approved the appointment of Dibyava Ghosh, originally named President and Interim CEO in May 2026, as Chief Executive Officer.
Showing 9 reports • Page 1 • Category: all
Stay ahead of the market
Get weekly insights delivered to your inbox. No spam, just intelligence.



